Literature DB >> 16631882

Mild cognitive impairment.

Serge Gauthier1, Barry Reisberg, Michael Zaudig, Ronald C Petersen, Karen Ritchie, Karl Broich, Sylvie Belleville, Henry Brodaty, David Bennett, Howard Chertkow, Jeffrey L Cummings, Mony de Leon, Howard Feldman, Mary Ganguli, Harald Hampel, Philip Scheltens, Mary C Tierney, Peter Whitehouse, Bengt Winblad.   

Abstract

Mild cognitive impairment is a syndrome defined as cognitive decline greater than expected for an individual's age and education level but that does not interfere notably with activities of daily life. Prevalence in population-based epidemiological studies ranges from 3% to 19% in adults older than 65 years. Some people with mild cognitive impairment seem to remain stable or return to normal over time, but more than half progress to dementia within 5 years. Mild cognitive impairment can thus be regarded as a risk state for dementia, and its identification could lead to secondary prevention by controlling risk factors such as systolic hypertension. The amnestic subtype of mild cognitive impairment has a high risk of progression to Alzheimer's disease, and it could constitute a prodromal stage of this disorder. Other definitions and subtypes of mild cognitive impairment need to be studied as potential prodromes of Alzheimer's disease and other types of dementia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16631882     DOI: 10.1016/S0140-6736(06)68542-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  644 in total

Review 1.  Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans.

Authors:  Paul S Aisen; Ronald C Petersen; Michael C Donohue; Anthony Gamst; Rema Raman; Ronald G Thomas; Sarah Walter; John Q Trojanowski; Leslie M Shaw; Laurel A Beckett; Clifford R Jack; William Jagust; Arthur W Toga; Andrew J Saykin; John C Morris; Robert C Green; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

2.  Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease.

Authors:  Mary Sano; Rema Raman; Jennifer Emond; Ronald G Thomas; Ronald Petersen; Lon S Schneider; Paul S Aisen
Journal:  Alzheimer Dis Assoc Disord       Date:  2011 Apr-Jun       Impact factor: 2.703

Review 3.  The concept of FDG-PET endophenotype in Alzheimer's disease.

Authors:  Emmanuel H During; R S Osorio; F M Elahi; L Mosconi; M J de Leon
Journal:  Neurol Sci       Date:  2011-06-01       Impact factor: 3.307

4.  A two-year follow-up of cognitive deficits and brain perfusion in mild cognitive impairment and mild Alzheimer's disease.

Authors:  Montserrat Alegret; Gemma Cuberas-Borrós; Georgina Vinyes-Junqué; Ana Espinosa; Sergi Valero; Isabel Hernández; Isabel Roca; Agustín Ruíz; Maitée Rosende-Roca; Ana Mauleón; James T Becker; Joan Castell-Conesa; Lluís Tárraga; Mercè Boada
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

5.  Reduced interhemispheric inhibition in mild cognitive impairment.

Authors:  Ryosuke Tsutsumi; Ritsuko Hanajima; Masashi Hamada; Yuichiro Shirota; Hideyuki Matsumoto; Yasuo Terao; Shinya Ohminami; Yoshihiro Yamakawa; Hiroyuki Shimada; Shoji Tsuji; Yoshikazu Ugawa
Journal:  Exp Brain Res       Date:  2012-01-11       Impact factor: 1.972

6.  An exploration of subgroups of mild cognitive impairment based on cognitive, neuropsychiatric and functional features: analysis of data from the National Alzheimer's Coordinating Center.

Authors:  John J Hanfelt; Joanne Wuu; Ann B Sollinger; Melanie C Greenaway; James J Lah; Allan I Levey; Felicia C Goldstein
Journal:  Am J Geriatr Psychiatry       Date:  2011-11       Impact factor: 4.105

7.  Association of Klotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who Carry APOE4.

Authors:  Michael E Belloy; Valerio Napolioni; Summer S Han; Yann Le Guen; Michael D Greicius
Journal:  JAMA Neurol       Date:  2020-07-01       Impact factor: 18.302

8.  Mild Cognitive Impairment and Dementia Show Contrasting Associations with Risk of Cancer.

Authors:  Kimberly D van der Willik; Rikje Ruiter; Frank J Wolters; M Kamran Ikram; Bruno H Stricker; Michael Hauptmann; Annette Compter; Sanne B Schagen; M Arfan Ikram
Journal:  Neuroepidemiology       Date:  2018-05-14       Impact factor: 3.282

Review 9.  Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease.

Authors:  Lisa Mosconi; Alberto Pupi; Mony J De Leon
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

10.  Variation in Variables that Predict Progression from MCI to AD Dementia over Duration of Follow-up.

Authors:  Shanshan Li; Ozioma Okonkwo; Marilyn Albert; Mei-Cheng Wang
Journal:  Am J Alzheimers Dis (Columbia)       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.